Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021

Rhea-AI Summary

Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, will host a conference call on March 30, 2021, at 4:30 p.m. ET to discuss its fourth quarter and full-year financial results for 2020. The event will also provide a business overview. Investors can access the call via phone or a live audio webcast available on Atea's website. Atea focuses on developing therapies for life-threatening viral diseases using a proprietary nucleotide prodrug platform.

BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, March 30, 2021 at 4:30 p.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2020, and to provide a business overview.

To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least five minutes prior to the start time, and refer to conference ID 3282077. A live audio webcast of the call with accompanying slide presentation will also be available in the Investors’ Events & Presentations section of the Company's website, https://ir.ateapharma.com/news-and-events/events-and-presentations. An archived webcast will be available on the Atea website approximately two hours after the event.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Investors:

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations 
212-362-1200
will.oconnor@sternir.com

Media:

Carol Guaccero
301-606-4722
contactus@ateapharma.com

FAQ

What date will Atea Pharmaceuticals report its financial results?

Atea Pharmaceuticals will report its financial results on March 30, 2021.

What will be discussed during Atea's conference call?

The conference call will discuss the fourth quarter and full-year financial results for 2020 and provide a business overview.

How can I access Atea Pharmaceuticals' conference call?

You can access the conference call by dialing (833) 301-1150 domestically or (914) 987-7391 internationally. A live audio webcast will also be available on Atea's website.

What is Atea Pharmaceuticals' focus in drug development?

Atea Pharmaceuticals focuses on developing therapies for life-threatening viral diseases, particularly using nucleotide prodrugs targeting ssRNA viruses.